FDA approves Pfizer Ibrance regimen for HR+, HER2+ metastatic breast cancer maintenance treatment

Pfizer Inc.

Pfizer Inc.

PFE

0.00
  • FDA cleared Pfizer’s Ibrance with trastuzumab, with or without pertuzumab, with endocrine therapy for frontline maintenance in HR+, HER2+ metastatic breast cancer.
  • Approval follows the Phase 3 PATINA trial, showing a 24% reduction in progression or death risk vs anti-HER2 therapy with endocrine therapy alone.
  • Pfizer said Ibrance is now the first CDK4/6 inhibitor indicated for HR+ metastatic breast cancer regardless of HER2 status.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260617408304) on June 24, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.